ANAB Anaptysbio Inc

Price (delayed)

$19.87

Market cap

$531.78M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$6.08

Enterprise value

$513.63M

Imsidolimab, previously known as ANB019, is an antibody that inhibits the function of the interleukin-36-receptor, or IL-36R, which AnaptysBio plans to initially develop as a potential first-in-class therapy for patients ...

Highlights

ANAB's revenue has soared by 67% YoY and by 15% from the previous quarter

The company's gross profit has surged by 67% YoY and by 15% QoQ

Anaptysbio's equity has plunged by 66% YoY and by 27% from the previous quarter

The company's quick ratio fell by 37% YoY

Sector: Healthcare

Industry: Biotechnology

Website: http://www.anaptysbio.com

Peers: OCX OGEN OLMA OMER

Key stats

What are the main financial stats of ANAB

Market

Shares outstanding

26.76M

Market cap

$531.78M

Enterprise value

$513.63M

Valuations

Price to earnings (P/E)

N/A

Price to book (P/B)

5.99

Price to sales (P/S)

31.18

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

29.94

Earnings

Revenue

$17.16M

EBIT

-$163.62M

EBITDA

-$161.25M

Free cash flow

-$121.61M

Per share

EPS

-$6.08

Free cash flow per share

-$4.52

Book value per share

$3.32

Revenue per share

$0.64

TBVPS

$16.8

Balance sheet

Total assets

$452.39M

Total liabilities

$364.29M

Debt

$17.81M

Equity

$88.1M

Working capital

$369.39M

Liquidity

Debt to equity

0.2

Current ratio

10.87

Quick ratio

10.62

Net debt/EBITDA

0.11

Margins

EBITDA margin

-939.8%

Gross margin

100%

Net margin

-953.7%

Operating margin

-958.3%

Efficiency

Return on assets

-32.6%

Return on equity

-119.4%

Return on invested capital

-37.7%

Return on capital employed

-39.4%

Return on sales

-953.7%

Dividend

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

ANAB stock price

How has the Anaptysbio stock price performed over time

Intraday

0.2%

1 week

-12.51%

1 month

-14.61%

1 year

-13.16%

YTD

-7.24%

QTD

-11.77%

Financial performance

How have Anaptysbio's revenue and profit performed over time

Revenue

$17.16M

Gross profit

$17.16M

Operating income

-$164.41M

Net income

-$163.62M

Gross margin

100%

Net margin

-953.7%

ANAB's revenue has soared by 67% YoY and by 15% from the previous quarter

The company's gross profit has surged by 67% YoY and by 15% QoQ

ANAB's operating income is down by 43% year-on-year and by 11% since the previous quarter

The net income has decreased by 27% YoY and by 11% QoQ

Growth

What is Anaptysbio's growth rate over time

Valuation

What is Anaptysbio stock price valuation

P/E

N/A

P/B

5.99

P/S

31.18

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

29.94

ANAB's EPS is down by 33% year-on-year and by 12% since the previous quarter

ANAB's P/B is 140% higher than its 5-year quarterly average of 2.5 and 39% higher than its last 4 quarters average of 4.3

Anaptysbio's equity has plunged by 66% YoY and by 27% from the previous quarter

ANAB's revenue has soared by 67% YoY and by 15% from the previous quarter

The stock's price to sales (P/S) is 38% less than its 5-year quarterly average of 50.6 and 24% less than its last 4 quarters average of 41.1

Efficiency

How efficient is Anaptysbio business performance

Anaptysbio's return on equity has shrunk by 173% YoY and by 46% QoQ

The ROA has shrunk by 56% YoY and by 19% QoQ

The return on invested capital has dropped by 53% year-on-year and by 19% since the previous quarter

ANAB's return on sales is up by 24% year-on-year and by 3.5% since the previous quarter

Dividends

What is ANAB's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for ANAB.

Financial health

How did Anaptysbio financials performed over time

The total assets is 24% more than the total liabilities

The current ratio has declined by 37% year-on-year

The company's quick ratio fell by 37% YoY

ANAB's debt is 80% less than its equity

ANAB's debt to equity has surged by 186% year-on-year and by 33% since the previous quarter

Anaptysbio's equity has plunged by 66% YoY and by 27% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.